Eduard A. Struys

Eduard A. Struys

Auto-generated profile, based on publicly available information

Eduard A. Struys

Amsterdam Gastroenterology Endocrinology Metabolism Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 August 2023 in Science Advances
Verified
Journal Article
Open access
FAFatemeh Mirzadeh Azad
Fatemeh Mirzadeh Azad
ESEduard A. Struys
Eduard A. Struys
VWVictoria Wingert
Victoria Wingert
Luciana HannibalLuciana Hannibal
Luciana Hannibal
Ken MillsKen Mills
Ken Mills
YAYaser Atlasi
Yaser Atlasi
Understanding mechanisms of epigenetic regulation in embryonic stem cells (ESCs) is of fundamental importance for stem cell and developmental biology. Here, we identify Spic , a member of the ETS family of transcription factors (TFs), as a marker of ground state pluripotency. We show that Spic is rapidly induced in ground state ESCs and in response to extracellular signal–regulated kinase (ERK) inhibition. We find that SPIC binds to enhancer elements and stabilizes NANOG binding to chromatin, particularly at genes involved in choline/one-carbon (1C) metabolism such as Bhmt , Bhmt2 , and Dmgdh . Gain-of-function and loss-of-function experiments revealed that Spic controls 1C metabolism and the flux of S -adenosyl methionine to S -adenosyl-L -homocysteine (SAM-to-SAH), thereby, modulating the levels of H3R17me2 and H3K4me3 histone marks in ESCs. Our findings highlight betaine-dependent 1C metabolism as a hallmark of ground state pluripotency primarily activated by SPIC. These findings underscore the role of uncharacterized auxiliary TFs in linking cellular metabolism to epigenetic regulation in ESCs.

21 February 2017
Verified
Book Chapter
Open access
PDF file
LBLisette M. Berends
Lisette M. Berends
ESEduard A. Struys
Eduard A. Struys
BRBirthe Roos
Birthe Roos
UHUlbe Holwerda
Ulbe Holwerda
EJErwin E. W. Jansen
Erwin E. W. Jansen
MWMirjam M. C. Wamelink
Mirjam M. C. Wamelink
Introduction. Guanidinoacetate methyltransferase (GAMT) deficiency is an inborn error of metabolism (IEM), clinically characterized by intellectual disability, developmental delay, seizures, and movement disorders. Biochemical diagnosis of GAMT deficiency is based on the measurement of creatine and guanidinoacetate in urine, plasma, or CSF and is confirmed genetically by DNA analysis or by enzyme assay in lymphoblasts or fibroblasts. To obtain enough cells, these cells need to be cultured for at least 1 month. A less time-consuming diagnostic functional test is needed, since GAMT deficiency is a candidate for newborn screening (NBS) programs, to be able to confirm or rule out this IEM after an initial positive result in the NBS. Methods. Stable-isotope-labeled 13C2-guanidinoacetate and 2H3-S-adenosylmethionine (SAM) were used, which are converted by GAMT present in lymphocyte extracts into 2H3-13C2-creatine. The formed 2H3-13C2-creatine was butylated and subsequently measured by liquid chromatography tandem mass-spectrometry (LC-MS/MS). Results. We measured GAMT enzyme activity in lymphocyte extracts of 24 controls, 3 GAMT deficient patients and of 2 parents proven to be carrier. Because GAMT activity decreases when isolation time after venipuncture increases, reference values were obtained for 2 control groups: isolation on the day of venipuncture (27–130 pmol/h/mg) and 1 day afterwards (15–146 pmol/h/mg). Deficient patients had no detectable GAMT activity. The two carriers had GAMT activity within the normal range. Conclusion. We designed a fast, less invasive, and valid method to measure GAMT activity in lymphocytes using LC-MS/MS analysis without the need of time-consuming and laborious cell culture.

21 February 2025 in Inflammatory Bowel Diseases
Verified
Journal Article
Open access
EVEva Vermeer
Eva Vermeer
ESEduard A Struys
Eduard A Struys
MLMarry Lin
Marry Lin
JLJohan Van Limbergen
Johan Van Limbergen
NBNanne De Boer
Nanne De Boer
RJRobert de Jonge
Robert de Jonge
Background and Aims: Therapeutic drug monitoring (TDM) of methotrexate (MTX) is challenging due to its pharmacokinetics and short plasma half-life. Intracellular MTX–polyglutamates (PG1–5), which accumulate over time, have not been assessed in pediatric inflammatory bowel disease (IBD). This study aimed to evaluate erythrocyte MTX-PG as a potential TDM tool in pediatric IBD. Methods: In this cross-sectional study, MTX-PG concentrations were measured in erythrocytes of children with IBD on stable low-dose MTX for at least 12 weeks using stable-isotope dilution liquid chromatography–tandem mass spectrometry. The influence of administration route, MTX dosage, and anthropometrics on MTX-PG concentrations was examined. Results: Seventy-eight patients were included, showing MTX-PG3 as the predominant subspecies (median 27.0 nmol/L) with a median MTX-PGtotal of 74.8 nmol/L. A higher MTX dose correlated significantly with elevated levels of MTX-PG3, MTX-PG4, MTX-PG5, and MTX-PGtotal (P < .01). Adjusted for body surface area, MTX dose remained significantly associated with higher MTX-PG concentrations (P < .01). However, comparison by administration route was limited due to a few patients on subcutaneous MTX (n = 4). Conclusions: We observed high interindividual variability in the reached erythrocyte MTX-PG concentrations. Body surface adjusted or unadjusted MTX dosage showed a positive linear correlation with erythrocyte MTX-PG concentrations in children with IBD. This is a prerequisite for TDM and provides a strong basis for further research into the relation between TDM of MTX, efficacy, and toxicity.

16 June 2026 in Metabolomics
Verified
Journal Article
Open access
PDF file
AWAranka Julia van Wesemael
Aranka Julia van Wesemael
RKRimke R. de Kroon
Rimke R. de Kroon
NFNina Frerichs
Nina Frerichs
MWMirjam Van Weissenbruch
Mirjam Van Weissenbruch
AKA. H. van Kaam
A. H. van Kaam
ERElise Roze
Elise Roze
Introduction: Fecal microbiome and metabolome alterations precede late-onset sepsis (LOS) in preterm infants, but clinical determinants of fecal amino acid (AA) composition and association with LOS development remain poorly understood. Objectives: This study assessed the early-life determinants of fecal AA composition and AA profiles prior to clinical LOS onset to improve pathophysiological understanding. Methods: Infants (< 28 weeks’ gestation) with non-staphylococcal LOS were included in a discovery (n = 12) and validation cohort (n = 8), each matched 1:1 to non-LOS controls (n = 20), based on gestational and postnatal age. Using targeted liquid chromatography-tandem mass-spectrometry, this study identified early-life determinants of fecal AAs, analyzing fecal samples collected at week 1 to 4 in controls. Additionally, AA profiles prior to LOS onset were assessed to improve pathophysiological understanding, analyzing samples at t0 and t-3 days from LOS-affected infants and controls. Results: The most common LOS pathogens were Escherichia coli (n = 8), Serratia species (n = 4), and Streptococcus agalactiae (n = 3). Postnatal age, full-enteral feeding status, probiotic administration, and delivery mode significantly influenced fecal AAs. In the discovery cohort, threonine and glutamine were significantly decreased in affected infants (median [Q1-Q3], threonine: 43.8 [29.3–66.3] vs. 64.5 [48.1–107.3] μmol/L, p = 0.02; glutamine: 19.0 [9.0–38.3] vs. 34.1 [27.0–69.8], p = 0.01), while the validation cohort solely showed a non-significant decrease of threonine. When combining both cohorts, threonine achieved an area under the curve of 0.65 (95%-CI: 0.53–0.76). Conclusions: These findings suggest several clinical characteristics influence fecal AAs, and altered threonine metabolism may contribute to LOS pathophysiology, warranting evaluation of related metabolites and multi-marker approaches in future studies.